0001104659-22-063506.txt : 20220520
0001104659-22-063506.hdr.sgml : 20220520
20220520174055
ACCESSION NUMBER: 0001104659-22-063506
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220519
FILED AS OF DATE: 20220520
DATE AS OF CHANGE: 20220520
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Hambleton Julie
CENTRAL INDEX KEY: 0001578771
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39044
FILM NUMBER: 22948975
MAIL ADDRESS:
STREET 1: C/O FIVE PRIME THERAPEUTICS, INC.
STREET 2: TWO CORPORATE DRIVE
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc.
CENTRAL INDEX KEY: 0001773427
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
BUSINESS PHONE: 203-883-9490
MAIL ADDRESS:
STREET 1: 100 WASHINGTON BOULEVARD
CITY: STAMFORD
STATE: CT
ZIP: 06902
4
1
tm2216253-2_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-05-19
0
0001773427
SpringWorks Therapeutics, Inc.
SWTX
0001578771
Hambleton Julie
C/O SPRINGWORKS THERAPEUTICS, INC.,
100 WASHINGTON BLVD.
STAMFORD,
CT
06902
1
0
0
0
Common Stock
2022-05-19
4
A
0
4818
0
A
5924
D
Stock Option (Right to Buy)
35.42
2022-05-19
4
A
0
15318
0
A
2032-05-19
Common Stock
15318
15318
D
This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Reflects a correction to the total number of securities beneficially owned, previously reported on a Form 4 filed on May 21, 2021.
This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
The options shall vest in full on the earlier of (1) May 19, 2023 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
/s/ Francis I. Perier, Jr as Attorney-in-Fact
2022-05-20